Skip to main content
Top
Published in: Tumor Biology 10/2014

01-10-2014 | Research Article

Expression profile of CYP1A1 and CYP1B1 enzymes in endometrial tumors

Authors: Ioannis Spyrou, Stavros Sifakis, Achilles Ploumidis, Alexandros E. Papalampros, Evangellos Felekouras, Aristidis M. Tsatsakis, Demetrios A. Spandidos, Vasilis P. Androutsopoulos

Published in: Tumor Biology | Issue 10/2014

Login to get access

Abstract

The cytochrome P450 CYP1A1 and CYP1B1 enzymes are phase I extrahepatic enzymes involved in the activation of pro-carcinogenic compounds to carcinogenic metabolites. Although differential overexpression of CYP1A1 and CYP1B1 has been documented at the messenger RNA (mRNA) and protein level, studies that have examined CYP1 expression by enzyme activity assays are limited. In the current study, the expression of CYP1A1 and CYP1B1 was investigated in a panel of human tumors of endometrial origin by quantitative reverse transcriptase PCR (qRT-PCR), Western blotting, and enzyme activity assays. The data revealed that approximately 36 % (5/14) and 43 % (6/14) of the endometrial tumors overexpressed CYP1A1 and CYP1B1 mRNA, whereas in 57 % of the endometrial tumors, CYP1 mRNA levels were downregulated. The mean mRNA levels of CYP1B1 and CYP1A1 in endometrial tumors did not show a significant difference compared to normal tissues (p > 0.05). Western blotting confirmed the qRT-PCR results and CYP1A1 and CYP1B1 proteins were shown to be downregulated in 7/14 (50 %) of the tumors and overexpressed in 4/14 (29 %) of the tumors. As regards to enzyme activity, 21 % (3/14) of the endometrial samples revealed elevated CYP1 activity levels across the tumor counterparts. Overall, the data suggest a putative downregulation of CYP1A1 and CYP1B1 expression in endometrial tumors, whereas overexpression of active CYP1 enzymes in 21 % of the tumors highlights the potential use of the latter enzymes as chemotherapeutic targets in endometrial cancer.
Literature
1.
go back to reference Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.CrossRefPubMed
2.
go back to reference Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92.CrossRefPubMed Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92.CrossRefPubMed
3.
go back to reference Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. 2004;95:1–6.CrossRefPubMed Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci. 2004;95:1–6.CrossRefPubMed
4.
go back to reference Schwarz D, Kisselev P, Ericksen SS, Szklarz GD, Chernogolov A, Honeck H, et al. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R), 18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol. 2004;67:1445–57.CrossRefPubMed Schwarz D, Kisselev P, Ericksen SS, Szklarz GD, Chernogolov A, Honeck H, et al. Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R), 18(S)-epoxyeicosatetraenoic acid. Biochem Pharmacol. 2004;67:1445–57.CrossRefPubMed
6.
go back to reference Kasai S, Ishigaki T, Takumi R, Kamimura T, Kikuchi H. Beta-catenin signaling induces CYP1A1 expression by disrupting adherens junctions in Caco-2 human colon carcinoma cells. Biochim Biophys Acta. 1830;2013:2509–16. Kasai S, Ishigaki T, Takumi R, Kamimura T, Kikuchi H. Beta-catenin signaling induces CYP1A1 expression by disrupting adherens junctions in Caco-2 human colon carcinoma cells. Biochim Biophys Acta. 1830;2013:2509–16.
7.
go back to reference Braeuning A, Kohle C, Buchmann A, Schwarz M. Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway. Toxicol Sci. 2011;122:16–25.CrossRefPubMed Braeuning A, Kohle C, Buchmann A, Schwarz M. Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway. Toxicol Sci. 2011;122:16–25.CrossRefPubMed
8.
go back to reference Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, et al. Tumor specific expression of Cytochrome P450 CYP1B1. Cancer Res. 1997;57:3026–31.PubMed Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD, et al. Tumor specific expression of Cytochrome P450 CYP1B1. Cancer Res. 1997;57:3026–31.PubMed
9.
go back to reference Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. 2005;65:3726–34.CrossRefPubMed Leung YK, Lau KM, Mobley J, Jiang Z, Ho SM. Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. Cancer Res. 2005;65:3726–34.CrossRefPubMed
10.
go back to reference Cheung YL, Kerr AC, McFadyen MCE, Melvin WT, Murray GI. Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumors. Cancer Lett. 1999;139:199–205.CrossRefPubMed Cheung YL, Kerr AC, McFadyen MCE, Melvin WT, Murray GI. Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumors. Cancer Lett. 1999;139:199–205.CrossRefPubMed
11.
go back to reference Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis. 1998;19:291–8.CrossRefPubMed Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ. Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis. 1998;19:291–8.CrossRefPubMed
13.
go back to reference Patterson LH, Murray GI. Tumor cytochrome P450 and drug activation. Curr Pharm Des. 2002;8:1335–47.CrossRefPubMed Patterson LH, Murray GI. Tumor cytochrome P450 and drug activation. Curr Pharm Des. 2002;8:1335–47.CrossRefPubMed
14.
go back to reference Androutsopoulos VP, Spyrou I, Ploumidis A, Papalampros AE, Kyriakakis M, Delakas D, et al. Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PLoS One. 2013;8:e82487.CrossRefPubMedPubMedCentral Androutsopoulos VP, Spyrou I, Ploumidis A, Papalampros AE, Kyriakakis M, Delakas D, et al. Expression profile of CYP1A1 and CYP1B1 enzymes in colon and bladder tumors. PLoS One. 2013;8:e82487.CrossRefPubMedPubMedCentral
16.
go back to reference Androutsopoulos VP, Spandidos DA. The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and p53/p21 upregulation. J Nutr Biochem. 2013;24:496–504.CrossRefPubMed Androutsopoulos VP, Spandidos DA. The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and p53/p21 upregulation. J Nutr Biochem. 2013;24:496–504.CrossRefPubMed
17.
go back to reference Saini S, Hinata H, Majid S, Dahiya R. Functional significance of cytochrome P450 CYP1B1 in endometrial carcinogenesis. Cancer Res. 2009;69:7038–45.CrossRefPubMed Saini S, Hinata H, Majid S, Dahiya R. Functional significance of cytochrome P450 CYP1B1 in endometrial carcinogenesis. Cancer Res. 2009;69:7038–45.CrossRefPubMed
18.
go back to reference Hevir N, Sinkovec J, Rizner TL. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: Lower levels of CYP1B1 and increased expression of S-COMT. Mol Cell Endocrinol. 2011;331:158–67.CrossRefPubMed Hevir N, Sinkovec J, Rizner TL. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: Lower levels of CYP1B1 and increased expression of S-COMT. Mol Cell Endocrinol. 2011;331:158–67.CrossRefPubMed
19.
go back to reference Pradhan S, Nagashri MN, Gopinath KS, Kumar A. Expression profiling of CYP1B1 in oral squamous cell carcinoma: counterintuitive downregulation in tumors. PLoS One. 2011;6:e27914.CrossRefPubMedPubMedCentral Pradhan S, Nagashri MN, Gopinath KS, Kumar A. Expression profiling of CYP1B1 in oral squamous cell carcinoma: counterintuitive downregulation in tumors. PLoS One. 2011;6:e27914.CrossRefPubMedPubMedCentral
20.
go back to reference Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab. 2008;9:129–43.CrossRefPubMed Pavek P, Dvorak Z. Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr Drug Metab. 2008;9:129–43.CrossRefPubMed
21.
go back to reference Liehr JC, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT. 4-hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci. 1995;92:9220–4.CrossRefPubMedPubMedCentral Liehr JC, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT. 4-hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci. 1995;92:9220–4.CrossRefPubMedPubMedCentral
23.
go back to reference Fichtner I, Monks A, Hose C, Stevens MF, Bradshaw TD. The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models. Breast Cancer Res Treat. 2004;87:97–107.CrossRefPubMed Fichtner I, Monks A, Hose C, Stevens MF, Bradshaw TD. The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models. Breast Cancer Res Treat. 2004;87:97–107.CrossRefPubMed
24.
go back to reference Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, et al. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther. 2013;12:27–37.CrossRefPubMed Sutherland M, Gill JH, Loadman PM, Laye JP, Sheldrake HM, Illingworth NA, et al. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther. 2013;12:27–37.CrossRefPubMed
Metadata
Title
Expression profile of CYP1A1 and CYP1B1 enzymes in endometrial tumors
Authors
Ioannis Spyrou
Stavros Sifakis
Achilles Ploumidis
Alexandros E. Papalampros
Evangellos Felekouras
Aristidis M. Tsatsakis
Demetrios A. Spandidos
Vasilis P. Androutsopoulos
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2240-2

Other articles of this Issue 10/2014

Tumor Biology 10/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine